Fat distribution in short-stature children born small for gestational age

Takatoshi Maeyama1, Shinobu Ida1, Shinsuke Onuma1

  • 1Department of Gastroenterology Nutrition and Endocrinology, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.

Insights

Growth hormone (GH) treatment in children born small for gestational age (SGA) did not increase obesity risk. While fat mass remained unchanged, GH altered fat distribution, increasing the visceral to subcutaneous adipose tissue ratio.

Area of Science:

  • Pediatric Endocrinology
  • Growth and Development
  • Body Composition Analysis

Background:

  • Children born small for gestational age (SGA) with catch-up growth face increased obesity risk.
  • Body composition and fat distribution in SGA children without catch-up growth, especially after growth hormone (GH) treatment, are not well understood.

Purpose of the Study:

  • To investigate body composition and fat distribution in prepubertal short-stature children born SGA.
  • To evaluate the effects of GH treatment on body composition and fat distribution in these children.

Main Methods:

  • 27 prepubertal short-stature children born SGA were studied.
  • Anthropometry, dual-energy X-ray absorptiometry for body composition, and computed tomography for fat distribution were used.
  • Measurements were taken before and 1 year after GH treatment.

Main Results:

  • Before GH treatment, SGA children exhibited lean phenotypes with lower visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) than reference values.
  • GH treatment increased height standard deviation scores (SDS) but did not affect body mass index SDS or total fat mass.
  • Percentage fat mass decreased, while the VAT/SAT ratio significantly increased post-treatment.

Conclusions:

  • Short-stature SGA children had VAT and SAT within or below reference ranges before and after GH treatment.
  • GH treatment appears to have no adverse effects on adiposity in short-stature SGA children.
  • GH treatment may alter fat distribution, specifically increasing the VAT/SAT ratio.
Abstract

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
187
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
158
Applications of Normal Distribution01:22

Applications of Normal Distribution

The normal distribution is a useful statistical tool. One of its practical applications is determining the door height after considering the normal distribution of heights of persons, such that many can pass through it easily without striking their heads. The normal distribution can also determine the probability of a person having a height less than a specific height.
The heights of 15 to 18-year-old males from Chile from 1984 to 1985 followed a normal distribution. The mean height is 172.36...
8.7K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
156